Next Investors logo grey

Dimerix to meet with US FDA for new drug guidance


Published 28-APR-2016 14:25 P.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Clinical stage biotechnology company Dimerix Limited (ASX:DXB) has filed a request to the US Food and Drug Administration (FDA) for a pre Investigational New Drug (IND) application meeting in relation to the Development Plan for DMX-200 in Focal Segmental Glomerularsclerosis (FSGS).

Dimerix anticipates its discussion on DMX-200 will be scheduled in late June and will enable receipt of critical planning information from the FDA in Q3 2016.

FSGS is a progressive form of kidney disease, accounting for 2.3% of patients with end-stage renal disease (ESRD).

Chronic kidney disease can result from diabetes, high blood pressure and diseases that cause inflammation specifically in the kidneys. It affects more than 26 million people in the United States alone.

Dimerix has been conducting preclinical testing of DMX-200 in models relevant for kidney disease and testing has shown a significant reduction in proteinuria, strongly supporting the potential of DMX-200 to improve the same condition in patients. The company has also commenced a phase II clinical study in patients with chronic kidney disease in Australia (further details below).

DMX-200 is unique in that it combines two existing drugs, a chemokine receptor CCR2 blocker (propagermanium) used for its anti-inflammatory properties, and an angiotensin II type I receptor blocker (irbesartan) which is registered in the USA for hypertension and treatment of diabetic nephropathy in certain patients.

Dimerix will be working closely with the FDA to gain clarity around its US chronic kidney disease program and clinical trial designs, specifically relating to DMX-200.

The FDA encourages entities developing drugs for Orphan Indications, to obtain guidance on the data necessary to warrant IND submission.

As such Dimerix is seek early agreement with the FDA on critical questions which will define the data and the development plans used to register the drug in the US.

“Discussing DMX-200 with the FDA will provide us with valuable clarity around our US chronic kidney disease program and clinical trial designs, and the nonclinical package which the FDA will require for each development stage, including ultimate registration requirements of DMX-200 for FSGS,” Dimerix Executive Chairman Dr James Williams said.

“This information should place Dimerix in a strong position to map out the registration pathway and is a critical step towards realising the commercial value of our lead asset DMX-200.”

The move comes on the back DMX-200 Phase II trials.

The DMX-200 Phase II Trial

This two-part trial is a single arm, open label study in adult patients with chronic kidney disease (with proteinuria). The primary end points are the incidence and severity of adverse events and the clinically significant changes in the safety profile of participants.

Part A is a dose escalation trial recruiting up to 30 patients. All patients recruited to the trial will be on stable irbesartan therapy, and will be treated with propagermanium dosed orally three times per day. Each patient will commence on 30mg PPG/day and the dose increased each 28 days to a maximum of 240mg/day, or until proteinuria is absent or reduced to a level the clinician considers acceptable.

The Company expects to carry out an interim analysis of the Part A data to confirm the safety of the therapy and observe any biomarker changes on up to 15 patients. It is expected interim data will be available during 2016.

Part B is an expansion study, in which up to 30 patients are recruited on the best dose identified from Part A.

The company expects to review the design of Part B in consultation with the FDA and in light of all data available to the company, prior to commencement of Part B.

These discussions will be in line with the company’s strategy of pursuing registration for an orphan indication in which the sufferers exhibit chronic kidney disease.

The company has achieved orphan designation for Focal Segmental Glomerulosclerosis (FSGS) from the FDA. The trial has commenced at four sites in Melbourne, Australia, and may be expanded into other jurisdictions to meet recruitment targets and regulatory goals.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.